| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 关于"东宝转债"恢复转股的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 债券代码：123214 特别提示： 根据《包头东宝生物技术股份有限公司向不特定对象发行可转换公司债券募集 说明书》相关规定，"东宝转债"将于本次权益分派股权登记日后的第一个交易日， 即2025年6月17日（除权除息日）起恢复转股。 敬请公司可转换公司债券持有人注意。 特此公告。 包头东宝生物技术股份有限公司 债券简称：东宝转债 转股起止时间：2024 年 2 月 5 日至 2029 年 7 月 30 日 暂停转股时间：2025 年 6 月 9 日起至 2025 年 6 月 16 日 恢复转股时间：2025 年 6 月 17 日 包头东宝生物技术股份有限公司（以下简称"公司"）因实施 2024 年度权益分 派，根据《包头东宝生物技术股份有限公司向不特定对象发行可转换 ...

Core Points - Dongbao Biological (300239) closed at 5.6 yuan on June 13, 2025, a 0.36% increase from the previous week's 5.58 yuan [1] - The company has a total market capitalization of 3.324 billion yuan, ranking 45th out of 50 in the bioproducts sector and 3972nd out of 5150 in the A-share market [1] Company Announcements - Dongbao Biological announced a cash dividend of 0.25 yuan per 10 shares (including tax) for the 2024 fiscal year, with the record date on June 16, 2025, and the ex-dividend date on June 17, 2025 [1][4] - The company will not issue new shares or use capital reserves for this dividend distribution, and the remaining undistributed profits will be carried forward to future distributions [1] - The adjusted cash dividend per 10 shares after the distribution will be approximately 0.245546 yuan (including tax) [1] Convertible Bond Adjustments - The conversion price for Dongbao Convertible Bonds (123214) will be adjusted from 6.65 yuan to 6.63 yuan per share, effective June 17, 2025 [2][4] - The company issued 455 million yuan worth of convertible bonds, with a total of 4.55 million bonds available for conversion [2] Share Buyback Adjustments - Following the 2024 dividend distribution, the maximum buyback price will be adjusted from 8.00 yuan to 7.98 yuan per share, with the expected buyback quantity adjusted to between 6,265,700 and 12,531,300 shares [3][4] - The buyback plan was approved on January 3, 2025, with a duration of 12 months [3]

Core Viewpoint - The company has announced a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 0.25 per 10 shares (tax included) to all shareholders, excluding shares held in the repurchase account [1][2][4]. Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting on May 15, 2025, with a cash dividend of RMB 0.25 per 10 shares (tax included) to all shareholders, without issuing bonus shares or capital reserve conversion [2][4]. - The total number of shares eligible for the dividend is calculated by deducting the repurchased shares from the total share capital as of the record date [3][4]. Dividend Calculation - The total cash dividend amount is adjusted based on the number of shares held after accounting for repurchased shares, resulting in a total cash dividend of RMB 14,575,863.32 (tax included) [3][4]. - The cash dividend per share is calculated as the total cash dividend divided by the adjusted total share capital, leading to a reference price adjustment for the ex-dividend date [6]. Key Dates - The record date for the dividend distribution is set for June 16, 2025, with the ex-dividend date on June 17, 2025 [5]. - Shareholders registered by the record date will receive the cash dividend directly into their accounts through their custodial securities companies [5]. Adjustments and Regulations - The company’s repurchased shares will not participate in this dividend distribution, and the conversion price of the company's convertible bonds will be adjusted accordingly [6].

Group 1 - The company has issued convertible bonds amounting to 455 million yuan, with a face value of 100 yuan per bond, totaling 4,550,000 bonds [1] - The initial conversion price for the convertible bonds was set at 6.67 yuan per share, which has been adjusted to 6.65 yuan per share effective from May 31, 2024 [2] - The adjusted conversion price after the latest cash dividend distribution is 6.63 yuan per share, effective from June 17, 2025 [4] Group 2 - The company will adjust the conversion price based on various corporate actions such as stock dividends, capital increases, and cash dividends, following specific formulas [1][2] - The company will disclose any adjustments to the conversion price through official announcements on the Shenzhen Stock Exchange or other designated media [2] - The company has a profit distribution plan for 2024, which does not include stock dividends or capital increases, and will carry forward undistributed profits to future distributions [3]

Core Viewpoint - The company, Dongbao Biological Technology Co., Ltd., has announced adjustments to its share repurchase plan following the implementation of its 2024 profit distribution plan, which includes a cash dividend distribution to shareholders [1][2]. Group 1: Share Repurchase Plan - The initial maximum repurchase price was set at RMB 8.00 per share, with a repurchase quantity ranging from 6,250,000 to 12,500,000 shares [1]. - The adjusted maximum repurchase price is now set at RMB 7.98 per share, with the new repurchase quantity estimated to be between 6,265,700 and 12,531,300 shares [1][4]. - The adjustment to the repurchase price and quantity will take effect from June 17, 2025, which is the ex-dividend date [1]. Group 2: Profit Distribution Plan - The profit distribution plan involves a cash dividend of RMB 0.25 per 10 shares (including tax), with no stock dividends or capital reserve transfers [2]. - The total share capital for the dividend distribution is based on the total shares minus the repurchased shares, resulting in a base of 583,034,533 shares for the cash dividend calculation [2]. - The record date for the profit distribution is set for June 16, 2025 [2]. Group 3: Regulatory Compliance - The company will adjust the repurchase price in accordance with regulations if it implements any dividend distributions, stock splits, or other equity-related actions during the repurchase period [3].

包头东宝生物技术股份有限公司 关于"东宝转债"转股价格调整的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 特别提示： 1、债券简称：东宝转债，债券代码：123214 2、本次调整前转股价格：6.65 元/股 3、本次调整后转股价格：6.63 元/股 4、本次调整后转股价格生效日期：2025 年 6 月 17 日(除权除息日) 一、关于可转债转股价格调整的相关规定 经中国证券监督管理委员会出具的《关于同意包头东宝生物技术股份有限公司 向不特定对象发行可转换公司债券注册的批复》(证监许可﹝2023﹞1517 号)同意注 册，公司向不特定对象发行 45,500.00 万元可转换为公司 A 股股票的可转换公司债 券，每张面值为人民币 100 元，共计 4,550,000 张。本次发行可转换公司债券募集 资金总额为 45,500.00 万元，本次发行可转换公司债券的上市时间为 2 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、包头东宝生物技术股份有限公司(以下简称"公司")2024 年度利润分配 预案为：以公司 2024 年度权益分派实施公告中确定的股权登记日当日的公司总 股本扣除回购专用证券账户中已回购股份数后的股本为基数，向全体股东每 10 股派发现金红利人民币 0.25 元(含税)，不送红股，不以资本公积金转增股本。 公司剩余未分配利润结转以后年度分配。 2、根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等 相关规定，公司回购专户中的股份不参与本次权益分派，故本次分派方案未以公 司现有总股本为分配基数。本次权益分派实施后，按公司现有总股本折算的每 10 股现金分红比例以及据此计算的除权除息参考价相关参数和公式计算如下： 按公司总股本（含公司回购专户已回 ...

证券代码：300239 证券简称：东宝生物 公告编号：2025-049 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于 2024 年度权益分派实施后调整 回购股份价格上限和数量的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 调整前回购价格上限、数量：不超过人民币 8.00 元/股（含），6,250,000 股(含) -12,500,000 股(含) 调整后回购价格上限、数量：不超过人民币 7.98 元/股（含），6,265,700 股(含) -12,531,300 股(含) 回购价格上限、数量调整起始日期：2025 年 6 月 17 日（除权除息日） 一、回购股份基本情况 包头东宝生物技术股份有限公司(以下简称"公司")于 2025 年 1 月 3 日召 开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了《关于回购 公司股份方案的议案》。根据相关法律法规及《公司章程》规定，本次回购股份 方案无需提交公司股东大会审议。使用公司自有资金和/或自筹资金以集中竞价 交易方式或法律法规允许的方式回购部分公 ...

Core Viewpoint - The company announces a temporary suspension of the conversion of its convertible bonds, effective from June 9, 2025, until the equity registration date for the 2024 annual equity distribution, to ensure the smooth implementation of the distribution [1] Group 1: Convertible Bonds Information - The convertible bonds (code: 123214; name: Dongbao Convertible Bonds) will be suspended for conversion during the specified period but will continue to trade normally [1] - The company will adjust the conversion price of the bonds in the event of stock dividends, capital increases, new share issuances, rights issues, or cash dividends, following a specific formula [1][2] - The adjustment formulas for the conversion price are detailed, including variables for stock dividends, new share prices, and cash dividends [1] Group 2: Price Adjustment Procedures - The company will publish announcements regarding the adjustment of the conversion price on the Shenzhen Stock Exchange website or other designated media, including the adjustment date and method [2] - In cases of share buybacks, mergers, splits, or other events affecting share categories or quantities, the company will adjust the conversion price to protect the rights of bondholders [2]

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 关于实施权益分派期间"东宝转债"暂停转股的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 包头东宝生物技术股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日召开 2024 年度股东大会审议通过了《2024 年度利润分配预案》，公司将于近日实施公 司 2024 年度权益分派。为保证本次权益分派的正常实施，根据《包头东宝生物技 术股份有限公司向不特定对象发行可转换公司债券募集说明书》中"转股价格的调 整方式及计算公式"条款的规定（详见附件）及有关业务办理指南的规定，自 2025 年 6 月 9 日起至 2024 年度权益分派股权登记日止，公司可转换公司债券（债券代 码：123214；债券简称：东宝转债） 将暂停转股，2024 年度权益分派股权登记日 后的第一个交易日起恢复转股。 在上述期间，"东宝转债"正常交易，敬请"东宝转债"债券持有人留意 ...